Name: Asia Pacific Imiglucerase Market, By Strength (400 IU and 200 IU), By Brand (Cerezyme, Abcertin, and Others), By Geography (China, India, Singapore, Thailand, Vietnam, Malaysia, Philippines, Indonesia, Cambodia, and Rest of Asia Pacific)
Brand: Coherent Market Insights
SKU: CMR-1c81f20de9
Price: 4500 USD
Availability: InStock

報告摘要

The Asia Pacific imiglucerase market is estimated to be valued at USD 192.7 Mn in 2026 and is expected to reach USD 262.1 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 4.5% from 2026 to 2033. The Asia Pacific imiglucerase market accounted for a significant portion of the rare diseases therapies sector, impelled by the rising demand for better treatments against Gaucher disease which is a lysosomal storage disorder resulting from the deficiency of the glucocerebrosidase enzyme. Imiglucerase which is predominantly available under the brand name of Cerezyme is the established enzyme replacement therapy (ERT) to treat the Type 1 and Type 3 Gaucher disease by replenishing the deficient enzyme activity and reducing glucocerebroside accumulation in affected organs. In the Asia Pacific region, the market augmentation is being assisted by the increasing incidence rates of rare genetic conditions, early disease diagnoses through superior screening techniques, and extensive government support to the orphan drug for Gaucher’s treatment in various economies including Japan, China, South Korea, Australia, and India. Expanding healthcare facilities, elevated rates of patient-to-biologic-therapy access, along with rare disease management schemes continues to escalate the demand for imiglucerase across the region. Market Dynamics The Asia Pacific imiglucerase market is primarily driven by the improving diagnosis of Gaucher disease, increasing awareness of rare genetic disorders, and expanding access to specialized biologic therapies across the region. Government support through orphan drug policies, strengthening healthcare infrastructure, and collaborations between pharmaceutical companies and healthcare providers are further enhancing treatment availability in key markets such as Japan, China, South Korea, Australia, and India. However, the growth of the market is limited by factors such as high cost of lifelong enzyme replacement therapy, limited reimbursement in several developing countries, and cold-chain distribution requirements continue to restrict market expansion. Nevertheless, there are abundant growth prospects due to factors such as increasing development of imiglucerase biosimilars, rising government initiatives for rare disease management, and expanding investment in rare disease research. Key Features of the Study • This report provides in-depth analysis of the Asia Pacific imiglucerase market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the Asia Pacific imiglucerase market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Sanofi, Takeda Pharmaceutical Company Limited, Pfizer Inc., Amicus Therapeutics, Inc., Recordati S.p.A., Chiesi Farmaceutici S.p.A., Alexion Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., ISU ABXIS Co., Ltd., and Avesthagen Limited • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The Asia Pacific imiglucerase market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Asia Pacific imiglucerase market Market Segmentation • Strength Insights (Revenue, USD Mn, 2021 - 2033) o 400 IU o 200 IU • Brand Insights (Revenue, USD Mn, 2021 - 2033) o Cerezyme o Abcertin o Others • Country Insights (Revenue, USD Mn, 2021 - 2033) o China o India o Singapore o Thailand o Vietnam o Malaysia o Philippines o Indonesia o Cambodia o Rest of Asia Pacific • Key Players Insights o Sanofi o Takeda Pharmaceutical Company Limited o Pfizer Inc. o Amicus Therapeutics, Inc. o Recordati S.p.A. o Chiesi Farmaceutici S.p.A. o Alexion Pharmaceuticals, Inc. o BioMarin Pharmaceutical Inc. o ISU ABXIS Co., Ltd. o Avesthagen Limited

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Asia Pacific Imiglucerase Market, By Strength  Asia Pacific Imiglucerase Market, By Brand  Asia Pacific Imiglucerase Market, By Country 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Industry Trends 4. Asia Pacific Imiglucerase Market, By Strength, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o 400 IU  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o 200 IU  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 5. Asia Pacific Imiglucerase Market, By Brand, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Cerezyme  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Abcertin  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 6. Asia Pacific Imiglucerase Market, By Country, 2021 - 2033, Value (USD Mn) o Introduction  Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)  Country Trends o China  Introduction  Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn) o India  Introduction  Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn) o Singapore  Introduction  Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn) o Thailand  Introduction  Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn) o Vietnam  Introduction  Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn) o Malaysia  Introduction  Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn) o Philippines  Introduction  Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn) o Indonesia  Introduction  Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn) o Cambodia  Introduction  Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn) o Rest of Asia Pacific  Introduction  Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn) 7. Competitive Landscape o Sanofi  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Takeda Pharmaceutical Company Limited  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Pfizer Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Amicus Therapeutics, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Recordati S.p.A.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Chiesi Farmaceutici S.p.A.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Alexion Pharmaceuticals, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o BioMarin Pharmaceutical Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o ISU ABXIS Co., Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Avesthagen Limited  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 8. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 9. References and Research Methodology o References o Research Methodology o About us *Browse 32 market data tables and 28 figures on ‘Imiglucerase Market’– Asia Pacific forecast to 2033

圖表清單 List of Tables & Figures

NA NA

提及公司

o Sanofio Takeda Pharmaceutical Company Limitedo Pfizer Inc.o Amicus TherapeuticsInc.o Recordati S.p.A.o Chiesi Farmaceutici S.p.A.o Alexion PharmaceuticalsInc.o BioMarin Pharmaceutical Inc.o ISU ABXIS Co.Ltd.o Avesthagen Limited

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們

Single User Price	$4,500 USD
Site License Price	$7,000 USD
Enterprisewide Price (Global Site License)	$10,000 USD

Asia Pacific Imiglucerase Market, By Strength (400 IU and 200 IU), By Brand (Cerezyme, Abcertin, and Others), By Geography (China, India, Singapore, Thailand, Vietnam, Malaysia, Philippines, Indonesia, Cambodia, and Rest of Asia Pacific)

授權報價

報告摘要

提及公司